MedTrace Logo

Fibrosis a New Pathological Actor in Adipose Tissue

NCT01655017 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2020-11-13

No results posted yet for this study

Summary

Adipose tissue (AT) has specific alterations in obesity in particular increased fibrosis amount compared to lean subjects. Fibrosis amount measured by immunohistochemistry on adipose biopsies appears to to predict weight loss response after a bariatric surgery. Non invasive tools to measure fibrosis needs to be validated. The investigators primary aim is to validate a new device able to measure adipose tissue stiffness.

Thus the investigators plan to compare the stiffness results obtained with the device to the quantification of fibrosis using immuno-chemistry in massively obese patient's candidates to a bariatric surgery.

Conditions

Interventions

PROCEDURE

biopsy

adipose tissue biopsy (to evaluate inflammation and fibrosis)

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Judith Aron-wisnewsky, MD · APHP

  • Karine Clement, MD, PhD · APHP

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-08
Primary Completion
2018-04-06
Completion
2018-04-06

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655017 on ClinicalTrials.gov